NRx Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.
Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls. The company’s Alzheimer’s candidate, NP-010 (simufilam), is being evaluated for its potential to restore neuronal function by targeting altered protein interactions in the brain. NRx has also initiated early investigations of NP-197, a candidate aimed at mitigating lingering symptoms in patients recovering from acute SARS-CoV-2 infection (Long COVID).
Founded in 2017, NRx Pharmaceuticals is headquartered in Northvale, New Jersey, and conducts preclinical and clinical studies across the United States and Europe. The company leverages strategic collaborations and outsourcing partnerships to support trial execution, regulatory filings and manufacturing scale‐up. Its management team comprises veteran drug‐development executives with experience in neurology, regulatory affairs and commercial strategy.
Under the leadership of President and Chief Executive Officer Mervyn G. Turner, NRx is working to advance its pipeline through key clinical milestones and regulatory interactions. The company’s approach centers on identifying well-characterized molecules with prior safety data and repurposing them for high‐value indications, aiming to streamline development timelines while addressing critical therapeutic gaps in neurology.
AI Generated. May Contain Errors.
